Business
OncBioMune CMO Begins Formulation Work on Tretinoin for Acute Promyelocytic Leukemia
OncBioMune CMO Begins Formulation Work on Tretinoin for Acute Promyelocytic Leukemia.
About this update from Theralink Technologies Inc.
[{"type":"text","content":"\nOncBioMune CMO Begins Formulation Work on Tretinoin for Acute Promyelocytic Leukemia\n\nOncBioMune CMO Begins Formulation Work on Tretinoin for Acute Promyelocytic Leukemia\n\nBATON ROUGE, LA--(Marketwired - May 23, 2017) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) (\"OncBioMune\" or the \"Company\"), a clinical stage biopharmaceutical company engaged in the development of novel cancer products and a proprietary vaccine technology, is pleased to announce that its contract manufacturing organization (CMO) has begun formulation work on tretinoin, also known as all-trans retinoic acid (ATRA), at its state-of-the-art, cGMP-compliant facility in Colombia. Tretinoin is an oral drug for the treatment of Acute Promyelocytic Leukemia (APL). OncBioMune has acquired commercialization rights for tretinoin throughout Mexico, Central America and Latin America from the leading South American CMO.There is no approved product in Mexico for the treatment of APL, an aggressive type of acute myeloid leukemia. As such, OncBioMune feels it is positioned to emerge as a market leader for the indication with tretinoin. Formulation work will be followed by stability studies, with expectations for commercialization of tretinoin under the OncBioMune brand across Mexico, Central America and Latin America in 2018.APL is characterized by too many immature blood-forming cells in the blood and bone marrow, leading to a shortage of healthy white and red blood cells and platelets. In addition to a patient facing an increased risk to bleeding and forming blood clots, persons with APL often cope with pain in the affected area, exhaustion, loss of appetite and weight loss. While APL can be diagnosed at any age, it is most common in middle-aged adults.Fortunately, APL is one of the most curable types of leukemia in developed countries, with tretinoin commonly prescribed as part of a therapeutic regimen. However, little therapeutic progress has been made in developing countries to deliver a measurable benefit with respect to complete hematological remission and disease-free survival, as is highly possible with tretinoin in the treatment protocol. Sign up for OncBioMune email alerts at: http://oncbiomune.com/email-alerts/. About OncBioMune Pharmaceuticals, Inc.OncBioMune Pharmaceuticals is a clinical-stage biopharmaceutical company engaged in the development of ...